The results showed that in the CGGA dataset, the expression of BRMS1 + AP − Mic − C6 was significantly detrimental to GBM immunotherapy, while in the TCGA cohort, the results were not significant (Supplementary Fig. 2I). Here, BRMS1 is linked to glioblastoma.